Ann Belien, CEO at Rejuvenate Biomed, explores the need for more treatment options for age-related diseases and the opportunities drug repurposing offers these conditions.

As the average global lifespan continues to rise, the prevalence of age-related diseases has become an increasing concern. Consequently, treatment options for those diseases are more needed than ever before. 

Ageing is a complex biological process associated with a variety of chronic diseases, including cardiovascular diseases, neurodegenerative disorders, cancer and metabolic syndromes. The traditional approach to developing new drugs for any disease, including those related to age, is time-consuming, costly, and fraught with high failure rates. Drug repurposing, which involves finding new uses for existing medications, offers a promising strategy to expedite the development of therapies for age-related conditions, allowing people to live healthier lives for longer. This approach leverages existing safety and efficacy data, reducing both the cost and time required to bring therapies to market. Here, I explore the significance of drug repurposing in the field of aging research from my personal experience at Rejuvenate Biomed. There are multiple benefits to repurposing drugs, with a large potential impact on healthcare. However, there are some challenges and considerations to take into account, including the importance of using the best and most advanced tools, such as artificial intelligence (AI), for drug selection to ensure the benefits play out.  

Benefits 

Cost and time efficiency: Developing a new drug from scratch typically takes 10-15 years and costs over a billion dollars. Drug repurposing, however, can significantly shorten this timeline and reduce costs, as repurposed drugs have already undergone extensive preclinical and clinical testing. Researchers can bypass much of the initial safety and toxicity assessments, expediting the clinical evaluation process allowing for faster and more cost-effective analysis. This acceleration is crucial for age-related therapeutics, where clinical trial timelines can be lengthy and timely interventions are necessary. 

Reduced risk of failure: The high failure rate in traditional drug development is a major hurdle, often due to unforeseen safety issues or lack of efficacy with drug candidates. Drugs that have already been approved for human use, however, have a well-characterised safety profile, reducing the likelihood of adverse events. Having this prior knowledge and information increases the probability of success in clinical trials for new indications, making repurposing a lower-risk strategy compared to de novo drug development.

Discovery of new drug mechanisms: Repurposing existing drugs can also lead to the discovery of novel mechanisms of action, enhancing the understanding of diseases. Many drugs have pleiotropic effects, meaning they can affect multiple biological pathways. For instance, metformin, originally developed as a diabetes medication, has shown potential in extending lifespan and reducing the incidence of age-related diseases through mechanisms that may involve improving mitochondrial function and reducing inflammation. These discoveries can open new avenues for understanding and targeting age-related diseases. 

Challenges 

Regulatory hurdles: While repurposing can streamline some aspects of drug development, navigating regulatory requirements for new indications can still be complex. Regulatory agencies require robust evidence of efficacy for new uses, and the standards for approval can vary depending on the therapeutic area and the specific repurposed drug. Collaborative efforts between researchers, regulatory bodies, and industry stakeholders are essential to harmonise these processes and facilitate the repurposing of drugs for age-related diseases. 

Intellectual property issues: One of the primary challenges of drug repurposing is navigating intellectual property (IP) rights. Pharmaceutical companies may be reluctant to invest in repurposing efforts if the original patent has expired, limiting the potential for exclusivity and profit. Developing creative business models and regulatory pathways, such as data or market exclusivity extension, is crucial to incentivise repurposing. 

Leveraging the right tools

While drug repurposing offers many benefits, selecting and evaluating the right drug candidates requires the appropriate platforms and tools. AI has become indispensable in this field for its ability to analyse vast amounts of biomedical data, including genetic information, clinical trial results and medical literature, to identify existing drugs with potential new uses. By using AI, we have the opportunity to untangle complex relationships between drugs and diseases that might be missed by traditional research methods and find new paths for treatments. This is especially important in dealing with multifactorial conditions, such as age-related diseases.

Conclusion

Drug repurposing offers a promising strategy to accelerate therapeutic development for age-related diseases. By leveraging existing drugs with known safety profiles, researchers can expedite the discovery of new treatments, ultimately improving health outcomes for the ageing population. Despite challenges, the potential benefits of drug repurposing are substantial. 

Increased investment in research, stakeholder collaboration, and innovative policy solutions are crucial to unlocking the full potential of drug repurposing to combat age-related diseases, paving the way for healthier aging and improved quality of life for older adults.

From DDW Volume 25 – Issue 4, Fall 2024 Read the digital issue

Ann BeliënAbout the author:

Dr Ann Beliën founded Rejuvenate Biomed in 2017, where she currently functions as CEO. Under her leadership, Rejuvenate Biomed transitioned from a discovery start-up to a clinical-stage biotech company. Beliën has successfully attracted international investors, securing funds from seed stage to series B.